Nova Southeastern University

nova.edu

Total trials

78

Active

22

Phase 3

2

Total enrollment

8,296

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 5 of 5 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
growth factors to help in regeneration1
Floradapt Intensive GI1
Etanercept1
Mifepristone1
N-Acetyl Cysteine1

Next readouts

  • 2025-09
  • 2026-02-24
  • 2026-04
  • 2027-06-30

Top conditions

  • Depression4
  • Low Back Pain3
  • Amyotrophic Lateral Sclerosis (ALS)3
  • ALS2
  • Dysphagia2
  • HIV Infection2
  • Substance Abuse2
  • Gulf War Illness2

Frequently asked questions about Nova Southeastern University

How many clinical trials does Nova Southeastern University have on ClinicalTrials.gov?
Nova Southeastern University is listed as the lead sponsor on 78 clinical trials in ClinicalTrials.gov, 22 of which are currently active (recruiting, enrolling, or ongoing).
How many of Nova Southeastern University's trials are in Phase 3?
2 of Nova Southeastern University's trials are in Phase 3, spread across 5 active drug programs.
What therapeutic areas does Nova Southeastern University focus on?
Nova Southeastern University's most-studied conditions on ClinicalTrials.gov are Depression, Low Back Pain, Amyotrophic Lateral Sclerosis (ALS), ALS, Dysphagia.
When are Nova Southeastern University's next clinical trial readouts?
Nova Southeastern University has 4 upcoming primary-completion readouts tracked here; the soonest is “TNF and Glucocorticoid Antagonist for GWI Associated Multi-symptom Disease Homeostasis Reset”, expected around 2025-09.